CytoDyn (CYDY) Cash from Financing Activities (2010 - 2026)
CytoDyn (CYDY) posted Cash from Financing Activities of $16.2 million for Q1 2026, up 13481.82% on a QoQ basis from -$121000.0 in Q3 2025, and up 77004.76% year-over-year from N/an in Q1 2025.
CytoDyn (CYDY) Cash from Financing Activities (2010 - 2026) Analysis & Trends
CytoDyn's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $16.2 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 77004.76% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $17.2 million (up 31.29% YoY) and the FY2025 annual result came in at $10.9 million, down 7.61% from the prior year.
- Cash from Financing Activities was $16.2 million for Q1 2026 at CytoDyn, up from -$121000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $16.2 million in Q1 2026 and bottomed at -$121000.0 in Q3 2025.
- A 5-year average of $5.4 million and a median of $3.6 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 101.25% — and 2026, when it surged 77004.76%.
- CytoDyn's Cash from Financing Activities stood at $2.3 million in 2022, then slumped by 71.97% to $654000.0 in 2023, then surged by 1378.13% to $9.7 million in 2024, then tumbled by 101.25% to -$121000.0 in 2025, then jumped by 13481.82% to $16.2 million in 2026.
- Business Quant data shows CYDY's Cash from Financing Activities at $16.2 million in Q1 2026, -$121000.0 in Q3 2025, and $1.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | 16.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 16.19 Mn |
| Feb 28, 2026 | 16.19 Mn |
| Aug 31, 2025 | -121,000.00 |
| Aug 31, 2025 | -121,000.00 |
| May 31, 2025 | 1.17 Mn |
| May 31, 2025 | 1.17 Mn |
| Feb 28, 2025 | 21,000.00 |
| Feb 28, 2025 | 21,000.00 |
| Aug 31, 2024 | 9.67 Mn |
| Aug 31, 2024 | 9.67 Mn |
| May 31, 2024 | 3.44 Mn |
| May 31, 2024 | 3.44 Mn |
| Feb 29, 2024 | 3.63 Mn |
| Feb 29, 2024 | 3.63 Mn |
| Nov 30, 2023 | 654,000.00 |
| Nov 30, 2023 | 654,000.00 |
| Aug 31, 2023 | 4.02 Mn |
| Aug 31, 2023 | 4.02 Mn |
| May 31, 2023 | 1.35 Mn |
| May 31, 2023 | 1.35 Mn |